Smarter Decisions,
Better Care

UpToDate synthesizes the most recent medical information into evidence-based practical recommendations clinicians trust to make the right point-of-care decisions.

  • Rigorous editorial process: Evidence-based treatment recommendations
  • World-Renowned physician authors: over 5,100 physician authors and editors around the globe
  • Innovative technology: integrates into the workflow; access from EMRs

Choose from the list below to learn more about subscriptions for a:


Subscribers log in here


Gestational trophoblastic neoplasia: Staging and treatment

Topic Outline

GRAPHICS

INTRODUCTION

Gestational trophoblastic disease (GTD) defines a group of conditions that arise from an aberrant fertilization event. The resulting proliferative process has the potential to develop into an invasive malignant neoplasm. The spectrum of GTD includes:

Hydatidiform mole (a molar pregnancy, which can be complete or partial)

Persistent/invasive mole

Choriocarcinoma

Placental site trophoblastic tumors (PSTT)

                                                                     

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Jun 2014. | This topic last updated: Feb 27, 2013.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2014 UpToDate, Inc.
References
Top
  1. Lurain JR, Brewer JI, Torok EE, Halpern B. Natural history of hydatidiform mole after primary evacuation. Am J Obstet Gynecol 1983; 145:591.
  2. Bagshawe KD, Lawler SD, Paradinas FJ, et al. Gestational trophoblastic tumours following initial diagnosis of partial hydatidiform mole. Lancet 1990; 335:1074.
  3. Sita-Lumsden A, Short D, Lindsay I, et al. Treatment outcomes for 618 women with gestational trophoblastic tumours following a molar pregnancy at the Charing Cross Hospital, 2000-2009. Br J Cancer 2012; 107:1810.
  4. Ayhan A, Tuncer ZS, Halilzade H, Küçükali T. Predictors of persistent disease in women with complete hydatidiform mole. J Reprod Med 1996; 41:591.
  5. Driscoll SG. Placental-site chorioma. The neoplasm of the implantation-site trophoblast. J Reprod Med 1984; 29:821.
  6. Feltmate CM, Genest DR, Wise L, et al. Placental site trophoblastic tumor: a 17-year experience at the New England Trophoblastic Disease Center. Gynecol Oncol 2001; 82:415.
  7. Papadopoulos AJ, Foskett M, Seckl MJ, et al. Twenty-five years' clinical experience with placental site trophoblastic tumors. J Reprod Med 2002; 47:460.
  8. Baergen RN, Rutgers JL, Young RH, et al. Placental site trophoblastic tumor: A study of 55 cases and review of the literature emphasizing factors of prognostic significance. Gynecol Oncol 2006; 100:511.
  9. Schmid P, Nagai Y, Agarwal R, et al. Prognostic markers and long-term outcome of placental-site trophoblastic tumours: a retrospective observational study. Lancet 2009; 374:48.
  10. Hassadia A, Gillespie A, Tidy J, et al. Placental site trophoblastic tumour: clinical features and management. Gynecol Oncol 2005; 99:603.
  11. Finkler NJ. Placental site trophoblastic tumor. Diagnosis, clinical behavior and treatment. J Reprod Med 1991; 36:27.
  12. Randall TC, Coukos G, Wheeler JE, Rubin SC. Prolonged remission of recurrent, metastatic placental site trophoblastic tumor after chemotherapy. Gynecol Oncol 2000; 76:115.
  13. Bower M, Paradinas FJ, Fisher RA, et al. Placental site trophoblastic tumor: molecular analysis and clinical experience. Clin Cancer Res 1996; 2:897.
  14. Kohorn EI. Negotiating a staging and risk factor scoring system for gestational trophoblastic neoplasia. A progress report. J Reprod Med 2002; 47:445.
  15. Gamer EI, Garrett A, Goldstein DP, Berkowitz RS. Significance of chest computed tomography findings in the evaluation and treatment of persistent gestational trophoblastic neoplasia. J Reprod Med 2004; 49:411.
  16. Committee on Practice Bulletins-Gynecology, American College of Obstetricians and Gynecologists. ACOG Practice Bulletin #53. Diagnosis and treatment of gestational trophoblastic disease. Obstet Gynecol 2004; 103:1365.
  17. Bakri Y, Berkowitz RS, Goldstein DP, et al. Brain metastases of gestational trophoblastic tumor. J Reprod Med 1994; 39:179.
  18. Soper JT. Identification and management of high-risk gestational trophoblastic disease. Semin Oncol 1995; 22:172.
  19. Kohorn EI. The new FIGO 2000 staging and risk factor scoring system for gestational trophoblastic disease: description and critical assessment. Int J Gynecol Cancer 2001; 11:73.
  20. FIGO Oncology Committee. FIGO staging for gestational trophoblastic neoplasia 2000. FIGO Oncology Committee. Int J Gynaecol Obstet 2002; 77:285.
  21. American Joint Committee on Cancer. Gestational Trophoblastic Tumors. In: AJCC Cancer Staging Manual, 7th, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010. p.437.
  22. Goldstein DP, Zanten-Przybysz IV, Bernstein MR, Berkowitz RS. Revised FIGO staging system for gestational trophoblastic tumors. Recommendations regarding therapy. J Reprod Med 1998; 43:37.
  23. DuBeshter B, Berkowitz RS, Goldstein DP, et al. Metastatic gestational trophoblastic disease: experience at the New England Trophoblastic Disease Center, 1965 to 1985. Obstet Gynecol 1987; 69:390.
  24. Mortakis AE, Braga CA. "Poor prognosis" metastatic gestational trophoblastic disease: the prognostic significance of the scoring system in predicting chemotherapy failures. Obstet Gynecol 1990; 76:272.
  25. Berkowitz RS, Goldstein DP. Gestational trophoblastic diseases. In: Principles and Practice of Gynecologic Oncology, 3rd, Hoskins WJ, Perez CA, Young RC (Eds), Lippincott, Williams and Wilkins, Philadelphia 2000. p.1127.
  26. Pecorelli S, Benedet JL, Creasman WT, Shepherd JH. FIGO staging of gynecologic cancer. 1994-1997 FIGO Committee on Gynecologic Oncology. International Federation of Gynecology and Obstetrics. Int J Gynaecol Obstet 1999; 64:5.
  27. Agarwal R, Teoh S, Short D, et al. Chemotherapy and human chorionic gonadotropin concentrations 6 months after uterine evacuation of molar pregnancy: a retrospective cohort study. Lancet 2012; 379:130.
  28. HERTZ R, LI MC, SPENCER DB. Effect of methotrexate therapy upon choriocarcinoma and chorioadenoma. Proc Soc Exp Biol Med 1956; 93:361.
  29. Kennedy AW. Persistent nonmetastatic gestational trophoblastic disease. Semin Oncol 1995; 22:161.
  30. Homesley HD. Single-agent therapy for nonmetastatic and low-risk gestational trophoblastic disease. J Reprod Med 1998; 43:69.
  31. Goldman ID, Matherly LH. Biochemical factors in the selectivity of leucovorin rescue: selective inhibition of leucovorin reactivation of dihydrofolate reductase and leucovorin utilization in purine and pyrimidine biosynthesis by methotrexate and dihydrofolate polyglutamates. NCI Monogr 1987; :17.
  32. Dorr RT, Von Hoff DD. Methotrexate. In: Cancer Chemotherapy Handbook, Dorr RT, Von Hoff DD (Eds), Appleton and Lange, Norwalk, CT 1994. p.694.
  33. Wong LC, Ngan HY, Cheng DK, Ng TY. Methotrexate infusion in low-risk gestational trophoblastic disease. Am J Obstet Gynecol 2000; 183:1579.
  34. Chan KK, Huang Y, Tam KF, et al. Single-dose methotrexate regimen in the treatment of low-risk gestational trophoblastic neoplasia. Am J Obstet Gynecol 2006; 195:1282.
  35. Foulmann K, Guastalla JP, Caminet N, et al. What is the best protocol of single-agent methotrexate chemotherapy in nonmetastatic or low-risk metastatic gestational trophoblastic tumors? A review of the evidence. Gynecol Oncol 2006; 102:103.
  36. Matsui H, Iitsuka Y, Seki K, Sekiya S. Comparison of chemotherapies with methotrexate, VP-16 and actinomycin-D in low-risk gestational trophoblastic disease. Remission rates and drug toxicities. Gynecol Obstet Invest 1998; 46:5.
  37. Garrett AP, Garner EO, Goldstein DP, Berkowitz RS. Methotrexate infusion and folinic acid as primary therapy for nonmetastatic and low-risk metastatic gestational trophoblastic tumors. 15 years of experience. J Reprod Med 2002; 47:355.
  38. Growdon WB, Wolfberg AJ, Goldstein DP, et al. Evaluating methotrexate treatment in patients with low-risk postmolar gestational trophoblastic neoplasia. Gynecol Oncol 2009; 112:353.
  39. Berkowitz RS, Goldstein DP, Bernstein MR. Methotrexate with citrovorum factor rescue as primary therapy for gestational trophoblastic disease. Cancer 1982; 50:2024.
  40. Berkowitz RS, Goldstein DP, Bernstein MR. Ten year's experience with methotrexate and folinic acid as primary therapy for gestational trophoblastic disease. Gynecol Oncol 1986; 23:111.
  41. Khan F, Everard J, Ahmed S, et al. Low-risk persistent gestational trophoblastic disease treated with low-dose methotrexate: efficacy, acute and long-term effects. Br J Cancer 2003; 89:2197.
  42. van Trommel NE, Massuger LF, Schijf CP, et al. Early identification of resistance to first-line single-agent methotrexate in patients with persistent trophoblastic disease. J Clin Oncol 2006; 24:52.
  43. Homesley HD, Blessing JA, Rettenmaier M, et al. Weekly intramuscular methotrexate for nonmetastatic gestational trophoblastic disease. Obstet Gynecol 1988; 72:413.
  44. Gleeson NC, Finan MA, Fiorica JV, et al. Nonmetastatic gestational trophoblastic disease. Weekly methotrexate compared with 8-day methotrexate-folinic acid. Eur J Gynaecol Oncol 1993; 14:461.
  45. Kang WD, Choi HS, Kim SM. Weekly methotrexate (50mg/m(2)) without dose escalation as a primary regimen for low-risk gestational trophoblastic neoplasia. Gynecol Oncol 2010; 117:477.
  46. Osborne RJ, Filiaci V, Schink JC, et al. Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a gynecologic oncology group study. J Clin Oncol 2011; 29:825.
  47. Kohorn EI. Is lack of response to single-agent chemotherapy in gestational trophoblastic disease associated with dose scheduling or chemotherapy resistance? Gynecol Oncol 2002; 85:36.
  48. McNeish IA, Strickland S, Holden L, et al. Low-risk persistent gestational trophoblastic disease: outcome after initial treatment with low-dose methotrexate and folinic acid from 1992 to 2000. J Clin Oncol 2002; 20:1838.
  49. Osathanondh R, Goldstein DP, Pastorfide GB. Actinomycin D as the primary agent for gestational trophoblastic disease. Cancer 1975; 36:863.
  50. Petrilli ES, Twiggs LB, Blessing JA, et al. Single-dose actinomycin-D treatment for nonmetastatic gestational trophoblastic disease. A prospective phase II trial of the Gynecologic Oncology Group. Cancer 1987; 60:2173.
  51. Twiggs LB. Pulse actinomycin D scheduling in nonmetastatic gestational trophoblastic neoplasia: cost-effective chemotherapy. Gynecol Oncol 1983; 16:190.
  52. Petrilli ES, Morrow CP. Actinomycin D toxicity in the treatment of trophoblastic disease: a comparison of the five-day course to single-dose administration. Gynecol Oncol 1980; 9:18.
  53. Chen LM, Lengyel ER, Bethan Powell C. Single-agent pulse dactinomycin has only modest activity for methotrexate-resistant gestational trophoblastic neoplasia. Gynecol Oncol 2004; 94:204.
  54. Mangili G, Garavaglia E, Frigerio L, et al. Management of low-risk gestational trophoblastic tumors with etoposide (VP16) in patients resistant to methotrexate. Gynecol Oncol 1996; 61:218.
  55. Hitchins RN, Holden L, Newlands ES, et al. Single agent etoposide in gestational trophoblastic tumours. Experience at Charing Cross Hospital 1978-1987. Eur J Cancer Clin Oncol 1988; 24:1041.
  56. Sung HC, Wu PC, Yang HY. Reevaluation of 5-fluorouracil as a single therapeutic agent for gestational trophoblastic neoplasms. Am J Obstet Gynecol 1984; 150:69.
  57. Song HZ, Yang XY, Xiang Y. Forty-five year's experience of the treatment of choriocarcinoma and invasive mole. Int J Gynaecol Obstet 1998; 60 Suppl 1:S77.
  58. Osborne R, Gerulath A. What is the best regimen for low-risk gestational trophoblastic neoplasia? A review. J Reprod Med 2004; 49:602.
  59. Osborne R, Filiaci V Schink J, et al. A randomized phase III trial comparing parenteral methotrexate and "pulsed" dactinomycin as primary management for low-risk gestational trophoblastic neoplasia: A Gynecologic Oncology Group study. Gynecol Oncol 2008; 108:S2.
  60. Alazzam M, Tidy J, Hancock BW, Osborne R. First line chemotherapy in low risk gestational trophoblastic neoplasia. Cochrane Database Syst Rev 2009; :CD007102.
  61. Lurain JR, Singh DK, Schink JC. Primary treatment of metastatic high-risk gestational trophoblastic neoplasia with EMA-CO chemotherapy. J Reprod Med 2006; 51:767.
  62. Escobar PF, Lurain JR, Singh DK, et al. Treatment of high-risk gestational trophoblastic neoplasia with etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine chemotherapy. Gynecol Oncol 2003; 91:552.
  63. Deng L, Zhang J, Wu T, Lawrie TA. Combination chemotherapy for primary treatment of high-risk gestational trophoblastic tumour. Cochrane Database Syst Rev 2013; 1:CD005196.
  64. Bower M, Newlands ES, Holden L, et al. EMA/CO for high-risk gestational trophoblastic tumors: results from a cohort of 272 patients. J Clin Oncol 1997; 15:2636.
  65. Rustin GJ, Newlands ES, Lutz JM, et al. Combination but not single-agent methotrexate chemotherapy for gestational trophoblastic tumors increases the incidence of second tumors. J Clin Oncol 1996; 14:2769.
  66. Dobson LS, Lorigan PC, Coleman RE, Hancock BW. Persistent gestational trophoblastic disease: results of MEA (methotrexate, etoposide and dactinomycin) as first-line chemotherapy in high risk disease and EA (etoposide and dactinomycin) as second-line therapy for low risk disease. Br J Cancer 2000; 82:1547.
  67. Matsui H, Suzuka K, Iitsuka Y, et al. Combination chemotherapy with methotrexate, etoposide, and actinomycin D for high-risk gestational trophoblastic tumors. Gynecol Oncol 2000; 78:28.
  68. Curry SL, Blessing JA, DiSaia PJ, et al. A prospective randomized comparison of methotrexate, dactinomycin, and chlorambucil versus methotrexate, dactinomycin, cyclophosphamide, doxorubicin, melphalan, hydroxyurea, and vincristine in "poor prognosis" metastatic gestational trophoblastic disease: a Gynecologic Oncology Group study. Obstet Gynecol 1989; 73:357.
  69. Berkowitz RS, Goldstein DP, Bernstein MR. Modified triple chemotherapy in the management of high-risk metastatic gestational trophoblastic tumors. Gynecol Oncol 1984; 19:173.
  70. Jones WB, Cardinale C, Lewis JL Jr. Management of high-risk gestational trophoblastic disease--the Memorial Hospital experience. Int J Gynecol Cancer 1997; 7:27.
  71. El-Lamie IK, El Sayed HM, Badawie AG, et al. Evolution of treatment of high-risk metastatic gestational trophoblastic tumors: Ain Shams University experience. Int J Gynecol Cancer 2006; 16:866.
  72. Kim SJ, Bae SN, Kim JH, et al. Effects of multiagent chemotherapy and independent risk factors in the treatment of high-risk GTT--25 years experiences of KRI-TRD. Int J Gynaecol Obstet 1998; 60 Suppl 1:S85.
  73. Newlands ES, Mulholland PJ, Holden L, et al. Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/cyclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental site trophoblastic tumors. J Clin Oncol 2000; 18:854.
  74. Lurain JR, Nejad B. Secondary chemotherapy for high-risk gestational trophoblastic neoplasia. Gynecol Oncol 2005; 97:618.
  75. Newlands ES. The management of recurrent and drug-resistant gestational trophoblastic neoplasia (GTN). Best Pract Res Clin Obstet Gynaecol 2003; 17:905.
  76. Xiang Y, Sun Z, Wan X, Yang X. EMA/EP chemotherapy for chemorefractory gestational trophoblastic tumor. J Reprod Med 2004; 49:443.
  77. Powles T, Savage PM, Stebbing J, et al. A comparison of patients with relapsed and chemo-refractory gestational trophoblastic neoplasia. Br J Cancer 2007; 96:732.
  78. Newlands ES, Bower M, Holden L, et al. Management of resistant gestational trophoblastic tumors. J Reprod Med 1998; 43:111.
  79. Azab M, Droz JP, Theodore C, et al. Cisplatin, vinblastine, and bleomycin combination in the treatment of resistant high-risk gestational trophoblastic tumors. Cancer 1989; 64:1829.
  80. DuBeshter B, Berkowitz RS, Goldstein DP, Bernstein M. Vinblastine, cisplatin and bleomycin as salvage therapy for refractory high-risk metastatic gestational trophoblastic disease. J Reprod Med 1989; 34:189.
  81. Gordon AN, Kavanagh JJ, Gershenson DM, et al. Cisplatin, vinblastine, and bleomycin combination therapy in resistant gestational trophoblastic disease. Cancer 1986; 58:1407.
  82. Willemse PH, Aalders JG, Bouma J, Sleijfer DT. Chemotherapy-resistant gestational trophoblastic neoplasia treated successfully with cisplatin, etoposide, and bleomycin. Obstet Gynecol 1988; 71:438.
  83. Sutton GP, Soper JT, Blessing JA, et al. Ifosfamide alone and in combination in the treatment of refractory malignant gestational trophoblastic disease. Am J Obstet Gynecol 1992; 167:489.
  84. Garris PD, Gallup DG, Melton K. Long-term remission of previously resistant choriocarcinoma with a combination of etoposide, ifosfamide, and cisplatin. Gynecol Oncol 1995; 57:254.
  85. Piamsomboon S, Kudelka AP, Termrungruanglert W, et al. Remission of refractory gestational trophoblastic disease in the brain with ifosfamide, carboplatin, and etoposide (ICE): first report and review of literature. Eur J Gynaecol Oncol 1997; 18:453.
  86. Matsui H, Iitsuka Y, Suzuka K, et al. Salvage chemotherapy for high-risk gestational trophoblastic tumor. J Reprod Med 2004; 49:438.
  87. Matsui H, Suzuka K, Iitsuka Y, et al. Salvage combination chemotherapy with 5-fluorouracil and actinomycin D for patients with refractory, high-risk gestational trophoblastic tumors. Cancer 2002; 95:1051.
  88. Termrungruanglert W, Kudelka AP, Piamsomboon S, et al. Remission of refractory gestational trophoblastic disease with high-dose paclitaxel. Anticancer Drugs 1996; 7:503.
  89. Jones WB, Schneider J, Shapiro F, Lewis JL Jr. Treatment of resistant gestational choriocarcinoma with taxol: a report of two cases. Gynecol Oncol 1996; 61:126.
  90. Osborne R, Covens A, Mirchandani D, Gerulath A. Successful salvage of relapsed high-risk gestational trophoblastic neoplasia patients using a novel paclitaxel-containing doublet. J Reprod Med 2004; 49:655.
  91. Amikura T, Aoki Y, Banzai C, et al. Metastatic choriocarcinoma successfully treated with paclitaxel and carboplatin after interstitial lung disease induced by EMA-CO. Gynecol Oncol 2006; 102:573.
  92. Shorbagi A, Aksoy S, Kilickap S, Güler N. Successful salvage therapy of resistant gestational trophoblastic disease with ifosfamide and paclitaxel. Gynecol Oncol 2005; 97:722.
  93. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006; 24:3187.
  94. Hartenbach EM, Saltzman AK, Carter JR, Twiggs LB. A novel strategy using G-CSF to support EMA/CO for high-risk gestational trophoblastic disease. Gynecol Oncol 1995; 56:105.
  95. Hammond CB, Weed JC Jr, Currie JL. The role of operation in the current therapy of gestational trophoblastic disease. Am J Obstet Gynecol 1980; 136:844.
  96. Roberts JP, Lurain JR. Treatment of low-risk metastatic gestational trophoblastic tumors with single-agent chemotherapy. Am J Obstet Gynecol 1996; 174:1917.
  97. Soper JT, Evans AC, Conaway MR, et al. Evaluation of prognostic factors and staging in gestational trophoblastic tumor. Obstet Gynecol 1994; 84:969.
  98. Ngan HY, Odicino F, Maisonneuve P, et al. Gestational trophoblastic neoplasia. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006; 95 Suppl 1:S193.
  99. Gillespie AM, Liyim D, Goepel JR, et al. Placental site trophoblastic tumour: a rare but potentially curable cancer. Br J Cancer 2000; 82:1186.
  100. Society of Gynecologic Oncologists Clinical Practice Guidelines. Practice guidelines: gestational trophoblastic disease. Oncology (Williston Park) 1998; 12:455.
  101. Newlands ES, Bower M, Fisher RA, Paradinas FJ. Management of placental site trophoblastic tumors. J Reprod Med 1998; 43:53.
  102. Vardar MA, Altintas A. Placental-site trophoblastic tumor. Principles of diagnosis, clinical behaviour and treatment. Eur J Gynaecol Oncol 1995; 16:290.
  103. Hancock BW, Welch EM, Gillespie AM, Newlands ES. A retrospective comparison of current and proposed staging and scoring systems for persistent gestational trophoblastic disease. Int J Gynecol Cancer 2000; 10:318.
  104. Schink JC, Singh DK, Rademaker AW, et al. Etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine for the treatment of metastatic, high-risk gestational trophoblastic disease. Obstet Gynecol 1992; 80:817.
  105. Garner EI, Feltmate CM, Goldstein DP, Berkowitz RS. The curative effect of a second curettage in persistent trophoblastic disease: a retrospective cohort survey. Gynecol Oncol 2005; 99:3.
  106. World Health Organization Scientific Group on Gestational Trophoblastic Disease. In: Technical Report Series No. 692, WHO, Geneva, Switzerland 1983.
  107. Altintaş A, Vardar MA. Central nervous system involvement in gestational trophoblastic neoplasia. Eur J Gynaecol Oncol 2001; 22:154.
  108. Small W Jr, Lurain JR, Shetty RM, et al. Gestational trophoblastic disease metastatic to the brain. Radiology 1996; 200:277.
  109. Schechter NR, Mychalczak B, Jones W, Spriggs D. Prognosis of patients treated with whole-brain radiation therapy for metastatic gestational trophoblastic disease. Gynecol Oncol 1998; 68:183.
  110. Lurain JR, Singh DK, Schink JC. Role of surgery in the management of high-risk gestational trophoblastic neoplasia. J Reprod Med 2006; 51:773.
  111. van Trommel NE, Thomas CM, Massuger LF, Sweep FC. Second curettage in persistent trophoblastic disease (PTD): the need for univocal definition of PTD. Gynecol Oncol 2005; 99:250.
  112. Pezeshki M, Hancock BW, Silcocks P, et al. The role of repeat uterine evacuation in the management of persistent gestational trophoblastic disease. Gynecol Oncol 2004; 95:423.
  113. Sumi Y, Ozaki Y, Shindoh N, Katayama H. Placental site trophoblastic tumor: imaging findings. Radiat Med 1999; 17:427.
  114. Suzuka K, Matsui H, Iitsuka Y, et al. Adjuvant hysterectomy in low-risk gestational trophoblastic disease. Obstet Gynecol 2001; 97:431.
  115. Jones WB, Lewis JL Jr. Integration of surgery and other techniques in the management of trophoblastic malignancy. Obstet Gynecol Clin North Am 1988; 15:565.
  116. Jones WB, Wolchok J, Lewis JL Jr. The role of surgery in the management of gestational trophoblastic disease. Int J Gynecol Cancer 1996; 6:261.
  117. Mutch DG, Soper JT, Babcock CJ, et al. Recurrent gestational trophoblastic disease. Experience of the Southeastern Regional Trophoblastic Disease Center. Cancer 1990; 66:978.
  118. Pisal N, North C, Tidy J, Hancock B. Role of hysterectomy in management of gestational trophoblastic disease. Gynecol Oncol 2002; 87:190.
  119. Doumplis D, Al-Khatib K, Sieunarine K, et al. A review of the management by hysterectomy of 25 cases of gestational trophoblastic tumours from March 1993 to January 2006. BJOG 2007; 114:1168.
  120. Alazzam M, Hancock BW, Tidy J. Role of hysterectomy in managing persistent gestational trophoblastic disease. J Reprod Med 2008; 53:519.
  121. Leiserowitz GS, Webb MJ. Treatment of placental site trophoblastic tumor with hysterotomy and uterine reconstruction. Obstet Gynecol 1996; 88:696.
  122. Kohorn EI, McCarthy SM, Taylor KJ. Nonmetastatic gestational trophoblastic neoplasia. Role of ultrasonography and magnetic resonance imaging. J Reprod Med 1998; 43:14.
  123. Ha HK, Jung JK, Jee MK, et al. Gestational trophoblastic tumors of the uterus: MR imaging--pathologic correlation. Gynecol Oncol 1995; 57:340.
  124. Evans AC Jr, Soper JT, Clarke-Pearson DL, et al. Gestational trophoblastic disease metastatic to the central nervous system. Gynecol Oncol 1995; 59:226.
  125. Ishizuka T, Tomoda Y, Kaseki S, et al. Intracranial metastasis of choriocarcinoma. A clinicopathologic study. Cancer 1983; 52:1896.
  126. Athanassiou A, Begent RH, Newlands ES, et al. Central nervous system metastases of choriocarcinoma. 23 years' experience at Charing Cross Hospital. Cancer 1983; 52:1728.
  127. Ghaemmaghami F, Behtash N, Memarpour N, et al. Evaluation and management of brain metastatic patients with high-risk gestational trophoblastic tumors. Int J Gynecol Cancer 2004; 14:966.
  128. Yordan EL Jr, Schlaerth J, Gaddis O, Morrow CP. Radiation therapy in the management of gestational choriocarcinoma metastatic to the central nervous system. Obstet Gynecol 1987; 69:627.
  129. Cagayan MS, Lu-Lasala LR. Management of gestational trophoblastic neoplasia with metastasis to the central nervous system: A 12-year review at the Philippine General Hospital. J Reprod Med 2006; 51:785.
  130. Herrington S. Enhancing cure and palliation: radiation therapy in the treatment of metastatic gestational trophoblastic neoplasia. Semin Oncol 1995; 22:185.
  131. Newlands ES, Holden L, Seckl MJ, et al. Management of brain metastases in patients with high-risk gestational trophoblastic tumors. J Reprod Med 2002; 47:465.
  132. Rustin GJ, Newlands ES, Begent RH, et al. Weekly alternating etoposide, methotrexate, and actinomycin/vincristine and cyclophosphamide chemotherapy for the treatment of CNS metastases of choriocarcinoma. J Clin Oncol 1989; 7:900.
  133. Wright JD, Mutch DG. Treatment of high-risk gestational trophoblastic tumors. Clin Obstet Gynecol 2003; 46:593.
  134. Crawford RA, Newlands E, Rustin GJ, et al. Gestational trophoblastic disease with liver metastases: the Charing Cross experience. Br J Obstet Gynaecol 1997; 104:105.
  135. Wong LC, Choo YC, Ma HK. Hepatic metastases in gestational trophoblastic disease. Obstet Gynecol 1986; 67:107.
  136. Bakri YN, Subhi J, Amer M, et al. Liver metastases of gestational trophoblastic tumor. Gynecol Oncol 1993; 48:110.
  137. Grumbine FC, Rosenshein NB, Brereton HD, Kaufman SL. Management of liver metastasis from gestational trophoblastic neoplasia. Am J Obstet Gynecol 1980; 137:959.
  138. Lok CA, Reekers JA, Westermann AM, Van der Velden J. Embolization for hemorrhage of liver metastases from choriocarcinoma. Gynecol Oncol 2005; 98:506.
  139. Barnard DE, Woodward KT, Yancy SG, et al. Hepatic metastases of choriocarcinoma: a report of 15 patients. Gynecol Oncol 1986; 25:73.
  140. Tomoda Y, Arii Y, Kaseki S, et al. Surgical indications for resection in pulmonary metastasis of choriocarcinoma. Cancer 1980; 46:2723.
  141. Jones WB, Romain K, Erlandson RA, et al. Thoracotomy in the management of gestational choriocarcinoma. A clinicopathologic study. Cancer 1993; 72:2175.
  142. Saitoh K, Harada K, Nakayama H, et al. Role of thoracotomy in pulmonary metastases from gestational choriocarcinoma. J Thorac Cardiovasc Surg 1983; 85:815.
  143. Fleming EL, Garrett L, Growdon WB, et al. The changing role of thoracotomy in gestational trophoblastic neoplasia at the New England Trophoblastic Disease Center. J Reprod Med 2008; 53:493.
  144. Yang J, Xiang Y, Wan X, Yang X. The prognosis of gestational trophoblastic neoplasia patient with residual lung tumor after completing treatment. Gynecol Oncol 2006; 103:479.
  145. Dhillon T, Palmieri C, Sebire NJ, et al. Value of whole body 18FDG-PET to identify the active site of gestational trophoblastic neoplasia. J Reprod Med 2006; 51:879.
  146. Yingna S, Yang X, Xiuyu Y, Hongzhao S. Clinical characteristics and treatment of gestational trophoblastic tumor with vaginal metastasis. Gynecol Oncol 2002; 84:416.
  147. Berry E, Hagopian GS, Lurain JR. Vaginal metastases in gestational trophoblastic neoplasia. J Reprod Med 2008; 53:487.
  148. Tse KY, Chan KK, Tam KF, Ngan HY. 20-year experience of managing profuse bleeding in gestational trophoblastic disease. J Reprod Med 2007; 52:397.
  149. Lehman E, Gershenson DM, Burke TW, et al. Salvage surgery for chemorefractory gestational trophoblastic disease. J Clin Oncol 1994; 12:2737.
  150. Feng F, Xiang Y, Li L, et al. Clinical parameters predicting therapeutic response to surgical management in patients with chemotherapy-resistant gestational trophoblastic neoplasia. Gynecol Oncol 2009; 113:312.
  151. You B, Pollet-Villard M, Fronton L, et al. Predictive values of hCG clearance for risk of methotrexate resistance in low-risk gestational trophoblastic neoplasias. Ann Oncol 2010; 21:1643.
  152. Kerkmeijer LG, Thomas CM, Harvey R, et al. External validation of serum hCG cutoff levels for prediction of resistance to single-agent chemotherapy in patients with persistent trophoblastic disease. Br J Cancer 2009; 100:979.
  153. Golfier F, Labrousse C, Frappart L, et al. [Evaluation of treatment relating to gestational trophoblastic tumor registered to the French Trophoblastic Disease Reference Center (TDRC) in Lyon from 1999 to 2005]. Gynecol Obstet Fertil 2007; 35:205.
  154. Cole LA, Kohorn EI. The need for an hCG assay that appropriately detects trophoblastic disease and other hCG-producing cancers. J Reprod Med 2006; 51:793.
  155. Mitchell H, Bagshawe KD, Newlands ES, et al. Importance of accurate human chorionic gonadotropin measurement in the treatment of gestational trophoblast disease and testicular cancer. J Reprod Med 2006; 51:868.
  156. Ngan HY, Tam KF, Lam KW, Chan KK. Relapsed gestational trophoblastic neoplasia: A 20-year experience. J Reprod Med 2006; 51:829.
  157. Costa HL, Doyle P. Influence of oral contraceptives in the development of post-molar trophoblastic neoplasia--a systematic review. Gynecol Oncol 2006; 100:579.
  158. Braga A, Maestá I, Michelin OC, et al. Maternal and perinatal outcomes of first pregnancy after chemotherapy for gestational trophoblastic neoplasia in Brazilian women. Gynecol Oncol 2009; 112:568.
  159. Matsui H, Iitsuka Y, Suzuka K, et al. Early pregnancy outcomes after chemotherapy for gestational trophoblastic tumor. J Reprod Med 2004; 49:531.
  160. Blagden SP, Foskett MA, Fisher RA, et al. The effect of early pregnancy following chemotherapy on disease relapse and foetal outcome in women treated for gestational trophoblastic tumours. Br J Cancer 2002; 86:26.
  161. Berkowitz RS, Tuncer ZS, Bernstein MR, Goldstein DP. Management of gestational trophoblastic diseases: subsequent pregnancy experience. Semin Oncol 2000; 27:678.
  162. Amr MF. Return of fertility after successful chemotherapy treatment of gestational trophoblastic tumors. Int J Fertil Womens Med 1999; 44:146.
  163. Song HZ, Wu PC, Wang YE, et al. Pregnancy outcomes after successful chemotherapy for choriocarcinoma and invasive mole: long-term follow-up. Am J Obstet Gynecol 1988; 158:538.
  164. Rustin GJ, Booth M, Dent J, et al. Pregnancy after cytotoxic chemotherapy for gestational trophoblastic tumours. Br Med J (Clin Res Ed) 1984; 288:103.
  165. Garner EI, Lipson E, Bernstein MR, et al. Subsequent pregnancy experience in patients with molar pregnancy and gestational trophoblastic tumor. J Reprod Med 2002; 47:380.
  166. Lorigan PC, Sharma S, Bright N, et al. Characteristics of women with recurrent molar pregnancies. Gynecol Oncol 2000; 78:288.